Parkinson's disease is a neurodegenerative disorder and its etiology is unknown, numerous studies show how different environmental factors can influence the development of disease. miRNAs are involved in several pathologies and their dysregulation contribute to different pathologies, also in neurodegenerative such as Parkinson's disease, Alzheimer's disease, Huntington's disease and Amyotrophic lateral sclerosis. In this study, we profiled the expression of different candidate miRNAs: miR-155, miR-26a, miR-146a, and miR132, in PBMCs of L-dopa treated Parkinson patients and unaffected controls (HCs).We investigated the expression of miRNAs by RT-real time PCR, the results were subjected to statistical analysis. miRNA-155-5p was generally up-regulated in PD patients compared to HCs whereas miRNA-146a-5p was down-regulated in PD patients in comparison to HCs. It is interesting to point out that the expression of miR-155-5p was modified by levodopa treatment, in fact a down-regulation of miR-155-5p in PD patients with the highest dosage was observed. In conclusion, miRNA 155 could not only be a promising target for the anti-inflammatory therapy in PD but also a good candidate as a disease progression biomarker. The role of levodopa in modulating the levels of miRNA 155 requires further studies.
•Expression of miR-155, miR-26a, miR-146a, and miR132, in PBMCs of L-dopa treated Parkinson patients have been evaluated.•miRNA-155-5p was up-regulated in PD patients compared to HCs, and miRNA-146a-5p was down-regulated in PD patients vs HCs.</span>•We observed a down-regulation of miR-155-5p in PD patients with the highest dosage was observed.</span>•miRNA 155 could be a target for the anti-inflammatory therapy in PD, and a good candidate as a disease progression biomarker.
Keywords: Levo-dopa treatment; Neurodegeneration; Parkinson's disease; miRNA.